Financial Performance - The company incurred a net loss of $12.6 million and $13.0 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $333.6 million as of December 31, 2025 [263]. - The company has never generated commercial revenue and expects to continue incurring significant losses for the foreseeable future [263]. - As of December 31, 2025, the company had approximately $14.6 million in cash and cash equivalents, raising substantial doubt about its ability to continue as a going concern [268]. - The company’s financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to various factors [275]. - The company expects existing cash and cash equivalents, along with proceeds from a January 2026 private placement, to cover operating expenses and capital expenditures into Q1 2027 [277]. - Future capital requirements will depend on various factors, including the costs and results of clinical trials for product candidates APR-1051 and ATRN-119 [277]. - The company anticipates an increase in expenses related to planned operations and will finance cash needs through equity offerings, debt financings, and collaborations [278]. - The company may face dilution of stockholder ownership if additional capital is raised through equity or convertible debt securities [278]. Clinical Development Challenges - The company has paused further patient enrollment in certain clinical trials as it explores combination approaches for its product candidates [272]. - The company relies on third parties for conducting clinical trials, which may not perform satisfactorily, potentially affecting the company's operations [257]. - The company is substantially dependent on the success of its product candidates APR-1051 and ATRN-119, which are still in early stages of clinical development [256]. - The company may face challenges in establishing sales and marketing capabilities necessary for the commercialization of its product candidates [260]. - Patient enrollment in clinical trials is critical, and delays or difficulties in enrollment could significantly impact the company's ability to obtain necessary marketing approvals [312]. - The company is exploring combination approaches for ATRN-119, but current pauses in patient enrollment may hinder timely development [306]. - The company has limited experience in conducting clinical trials, which may affect the timely completion of pivotal trials for its product candidates [308]. - The design of clinical trials can significantly impact the results, and flaws may not be apparent until trials are advanced [324]. - The company may need to conduct additional clinical trials if initial results are negative or inconclusive, leading to increased costs and delays [336]. - The company may face challenges in recruiting suitable patients for trials, which could delay the approval process [335]. Regulatory and Compliance Risks - The company has never obtained marketing approval for any product candidate, and the approval process is expected to be expensive, time-consuming, and uncertain [260]. - Disruptions at regulatory agencies like the FDA could delay product development and approval processes, negatively impacting operations [289]. - Regulatory authorities may change approval requirements, potentially leading to narrower indications or additional post-marketing testing requirements [338]. - Ongoing regulatory requirements will govern the manufacturing, packaging, marketing, and distribution of approved products, with non-compliance risking withdrawal of approval [368]. - The company faces risks related to regulatory compliance and may be impacted by external factors such as public health situations that could affect the approval timeline [447]. Intellectual Property and Competition - The company’s patent portfolio includes method-of-use and formulation claims, but lacks composition of matter patents for its key product eprenetapopt, which may affect competitive positioning [401]. - The company faces risks related to intellectual property, including potential litigation and the need to defend patents against third-party challenges [400]. - The company may face significant costs and time commitments in defending its patents against challenges, which could distract from its core operations [418]. - The company may struggle to obtain necessary third-party intellectual property rights, which could hinder the development of its product candidates [421]. - The company may face significant damages for infringement if a court finds that its products infringe third-party patents, which could include treble damages for willful infringement [433]. - The company may face claims regarding the wrongful use of trade secrets by employees or consultants, which could lead to significant legal expenses and distract management [440]. - The company may not be able to protect its intellectual property rights adequately, which could lead to challenges in building brand recognition and market identity [446]. Market and Economic Environment - The political and economic environment in the U.S. could materially impact the company's operations and financial performance, particularly due to regulatory changes [291]. - The company is currently operating in a period of global economic uncertainty, which may adversely affect its business and financial condition [280]. - Inflation and rising interest rates have led to declines in the trading value of government securities, potentially impacting liquidity for financial institutions [296]. - The company may face challenges in accessing adequate funding sources due to instability in the financial services industry [297]. - The company faces substantial competition in the cancer drug sector, with competitors having greater financial resources and expertise [349]. - The commercial opportunity could be reduced if competitors develop safer, more effective, or less expensive drugs [351]. Commercialization and Sales Strategy - The company lacks a sales and marketing infrastructure and experience in selling pharmaceutical drugs, which could hinder commercialization efforts [359]. - Establishing sales and marketing capabilities or entering into agreements with third parties is critical for successful commercialization of approved product candidates [358][362]. - Delays in the commercial launch of product candidates could result in unnecessary expenses and lost investments [361]. - The company may not achieve sufficient market acceptance for its product candidates, impacting revenue generation and profitability [346]. - The company plans to build commercial infrastructure to market its product candidates directly, but may still enter strategic collaborations with larger pharmaceutical companies [386].

Financial Performance - Aprea reported a net loss of $2.5 million ($0.32 per basic share) for Q4 2025, an improvement from a net loss of $2.9 million ($0.49 per basic share) in Q4 2024[12]. - For the full year 2025, Aprea reported a net loss of $12.6 million ($1.93 per basic share), compared to a net loss of $13.0 million ($2.35 per basic share) in 2024[12]. - Net loss for the year ended December 31, 2025, was $12,599,569, compared to a net loss of $12,958,711 in 2024, indicating a 2.8% improvement[21]. - The net loss per share attributable to common stockholders for 2025 was $1.93, compared to $2.35 in 2024, reflecting an improvement of approximately 17.9%[21]. Cash and Assets - Cash and cash equivalents as of December 31, 2025, were $14.6 million, down from $22.8 million as of December 31, 2024[14]. - Total assets decreased from $23,979,493 in 2024 to $15,933,401 in 2025, a decline of approximately 33.5%[20]. - Total stockholders' equity decreased from $19,307,455 in 2024 to $12,441,682 in 2025, a decline of approximately 35.4%[20]. - The number of common shares outstanding increased from 5,481,055 in 2024 to 8,192,538 in 2025, an increase of about 49.4%[20]. Revenue and Expenses - Grant revenue for the year ended December 31, 2025, was $285,759, down from $1,502,581 in 2024, representing an 81% decrease[21]. - Total operating expenses decreased from $15,822,236 in 2024 to $13,519,595 in 2025, a reduction of about 14.5%[21]. - Research and development expenses for the year ended December 31, 2025, were $7,043,035, down from $9,363,537 in 2024, a decrease of approximately 25%[21]. - General and administrative expenses increased slightly from $6,458,699 in 2024 to $6,476,560 in 2025, an increase of about 0.3%[21]. - General and Administrative (G&A) expenses for Q4 2025 were $1.6 million, up from $1.1 million in Q4 2024, mainly due to increased personnel costs[12]. Research and Development - Research and Development (R&D) expenses for Q4 2025 were $1.0 million, significantly lower than $2.4 million in Q4 2024, primarily due to reduced costs associated with clinical trials[12]. - The ongoing ACESOT-1051 trial of APR-1051 has shown early clinical proof-of-concept with two patients achieving unconfirmed partial responses[5]. - APR-1051 is being evaluated in patients with PPP2R1A mutations, with one patient showing a 50% reduction in target lesion size and a significant drop in CA-125 levels[6][7]. - Aprea plans to enrich patient enrollment in the ACESOT-1051 trial for endometrial, colorectal, and HPV+ tumors, with further updates expected in Q2 2026[11]. - The recommended Phase 2 dose for ATRN-119 was determined to be 1,100 mg for once daily dosing, with further enrollment paused to explore combination approaches[11]. Financing Activities - Aprea completed two private placements in December 2025 and January 2026, raising gross proceeds of approximately $3.1 million and $5.6 million, respectively[11].

Core Insights - Aprea Therapeutics is experiencing strong momentum entering 2026, driven by significant progress in its clinical trials, particularly the ACESOT trial for APR-1051, which has shown early proof of clinical concept with two patients achieving unconfirmed partial responses [2][5] - The company has successfully strengthened its financial position through private placements, enhancing its ability to meet key development milestones [2][10] - Aprea's focus remains on developing targeted therapies for biomarker-defined cancers, with a commitment to improving patient outcomes and shareholder value [2][11] Business Updates - The ACESOT-1051 trial is a Phase 1 study evaluating APR-1051, a WEE1 kinase inhibitor, which has shown promising results in endometrial cancer patients with PPP2R1A mutations [3][5] - The company has appointed Eugene Kennedy, MD, as Chief Medical Advisor to support the next phase of clinical development [5][10] - APR-1051 has demonstrated safety and tolerability, with ongoing dose escalation and plans to enroll additional patients with relevant genomic alterations [6][10] Financial Results - For Q4 2025, Aprea reported an operating loss of $2.6 million, an improvement from a loss of $3.2 million in Q4 2024 [10][19] - Research and Development (R&D) expenses decreased to $1.0 million in Q4 2025 from $2.4 million in Q4 2024, primarily due to lower costs associated with clinical trials [10][19] - The company reported a net loss of $2.5 million ($0.32 per share) for Q4 2025, compared to a net loss of $2.9 million ($0.49 per share) in the same period of 2024 [10][19] Year-End Financial Overview - For the year ended December 31, 2025, Aprea reported an operating loss of $13.2 million, compared to a loss of $14.3 million in 2024 [10][14] - Grant revenues for 2025 were $0.3 million, down from $1.5 million in 2024 [10][14] - As of December 31, 2025, the company had cash and cash equivalents of $14.6 million, down from $22.8 million in 2024, but believes it has sufficient funds to meet projected operating expenses into Q1 2027 [10][17]

Aprea Therapeutics FY Conference Summary Company Overview - **Company**: Aprea Therapeutics (NasdaqCM:APRE) - **Focus**: Precision oncology targeting the DNA damage response pathway - **Lead Program**: APR-1051, a next-generation WEE1 inhibitor - **Other Program**: ATRN-119, a macrocyclic ATR inhibitor [2][3] Core Points and Arguments Drug Development Strategy - Aprea aims to transition from traditional chemotherapy to precision-guided oncology, focusing on matching drugs with specific diseases based on biomarkers [3][4] - The company has three clinical programs targeting the DNA damage response pathway, with a primary focus on the WEE1 inhibitor, APR-1051 [4] Competitive Landscape - Previous attempts by Merck and AstraZeneca to develop WEE1 inhibitors faced challenges with therapeutic windows, leading to halted developments [5][6] - Aprea has redesigned its molecules to avoid liabilities seen in competitor programs, showing early signs of tumor reduction without significant toxicities [6][7] Clinical Data and Efficacy - Initial results from the dose escalation study indicate a minimum efficacious dose of 150 mg, with responses showing a 50% reduction in target lesions and a 90% reduction in biomarkers [8][10] - The drug appears well-tolerated, with minimal adverse effects reported, primarily nausea and fatigue [12][13] - Aprea is focusing on enrolling patients with specific mutations (e.g., PPP2R1A, FBXW7, HPV) to enhance the likelihood of positive responses [7][10][20] Future Development Plans - The company plans to continue dose escalation, aiming for higher doses to widen the therapeutic index and increase the number of responders [10][20] - Aprea has secured financing to support the enrollment of additional patients and to de-risk the next phase of development [10][24] Safety and Tolerability - The safety profile of APR-1051 is favorable, with no significant drug-related toxicities observed to date [20][23] - The company emphasizes the importance of maintaining a clean safety profile to differentiate its targeted therapy from traditional chemotherapy [20][23] Additional Important Content Combination Therapy Potential - Aprea is exploring combination therapies, particularly with PD-1 inhibitors, showing promising preclinical synergy [21][22] - The company aims to avoid overlapping toxicities in combination treatments, which could enhance efficacy while minimizing side effects [22][40] Market Position and Analyst Ratings - Aprea's market valuation is perceived as lacking fundamentals, presenting an asymmetric investment opportunity [24] - All covering analysts currently rate Aprea as a "buy" with higher price targets, indicating confidence in the company's future prospects [24] Timeline for Data Release - Aprea anticipates completing dose escalation by Q3 2026, with updates on clinical data expected as results become available [42][41] This summary encapsulates the key points from the Aprea Therapeutics FY Conference, highlighting the company's strategic focus, clinical progress, and future plans in the oncology space.

Core Viewpoint - Aprea Therapeutics shares are experiencing an increase following the announcement of additional preliminary data from the Phase 1 trial of APR-1051, a WEE1 kinase inhibitor [1] Group 1: Cancer Trial Data - A second unconfirmed partial response was reported in a patient with advanced endometrial cancer, showing a 50% reduction in target lesion measurements [2] - CA-125 tumor biomarker levels decreased significantly from 362 U/mL at baseline to 47 U/mL, indicating promising anti-tumor activity [2] Group 2: Trial Progress and Future Plans - Enrollment in the 220 mg dose cohort is ongoing, with plans to expand the study to include more patients with specific genetic alterations [3] - The trial aims to evaluate the safety and efficacy of APR-1051, with further updates expected in the second quarter of 2026 [3] Group 3: Analyst Consensus & Recent Actions - The stock currently carries a Buy Rating, with Aprea Therapeutics shares up 16.62% at $0.70 at the time of publication [4] - Recent analyst actions include Wedbush rating it as Outperform with a target lowered to $7.00 and HC Wainwright & Co. maintaining a Buy rating with a target lowered to $4.00 [4]

Core Viewpoint - Aprea Therapeutics announced preliminary data from the Phase 1 ACESOT-1051 trial for its WEE1 kinase inhibitor APR-1051, showing promising anti-tumor activity in patients with advanced endometrial cancer, particularly those with PPP2R1A mutations [1][5]. Trial Findings - The trial has reported a second unconfirmed partial response in a patient with advanced endometrial cancer at the 220 mg dose level, with a 50% reduction in target lesion measurements and a significant drop in the tumor biomarker CA-125 from 362 U/mL to 47 U/mL, representing an 87% decrease [2][3]. - The trial has treated a total of 22 patients at doses ranging from 10 mg to 220 mg, with the ongoing evaluation of safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity [6][10]. - Two patients with endometrial cancer harboring PPP2R1A mutations achieved unconfirmed partial responses at their first scan, observed at the 150 mg and 220 mg dose levels [8]. Safety and Tolerability - The treatment has been well tolerated, with only Grade 1 treatment-emergent adverse effects reported in the responding patient [3][7][14]. - The good safety profile supports the development strategy of differentiated WEE1 inhibition, aiming for an improved therapeutic index [5][7]. Future Directions - The company plans to expand enrollment in the 220 mg dose cohort, particularly focusing on patients with PPP2R1A endometrial and HPV-positive head and neck squamous cell carcinoma [9]. - Further updates from the trial are expected in the second quarter of 2026, reinforcing the ongoing commitment to advancing APR-1051 [4][10].

Core Viewpoint - Aprea Therapeutics, Inc. is set to provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting its innovative cancer therapies that target cancer-specific vulnerabilities while minimizing harm to healthy cells [1]. Group 1: Company Overview - Aprea is a clinical-stage biopharmaceutical company focused on developing therapies that exploit cancer cell mutations to treat various cancer types, including ovarian, endometrial, colorectal, and head and neck squamous cell carcinoma [3]. - The company's lead programs include APR-1051, an oral small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both currently in clinical development for solid tumor indications [4]. Group 2: Presentation Details - The corporate update will be presented virtually on February 26, 2026, at 8:40 am EST, with a webcast available for 90 days [2]. - Investors interested in one-on-one meetings with Aprea management during the conference can contact their Oppenheimer representative [2].

Core Insights - Aprea Therapeutics has expanded its global intellectual property estate with new patents granted in 2025 in Australia and Japan, enhancing protection for its WEE1 and ATR programs, expected to provide exclusivity until 2045 [1][3] - The lead WEE1 inhibitor candidate, APR-1051, is currently in Phase 1 trials, showing early clinical proof of concept, with multiple data readouts anticipated in 2026 [1][3] - Aprea's robust patent strategy aims to secure long-term commercial value and de-risk clinical development by protecting proprietary molecules and therapeutic applications [2][3] WEE1 Program - The WEE1 inhibitor APR-1051 is being evaluated in the ACESOT-1051 Phase 1 clinical trial for advanced/metastatic solid tumors with specific gene alterations [3] - The WEE1 patent portfolio includes one provisional U.S. patent application, two pending U.S. applications, one issued patent in Australia, and 13 pending applications internationally, with core patents expected to provide protection through 2042 [3] ATR Program - The ATR inhibitor ATRN-119 is under evaluation in the ABOYA-119 clinical trial as a monotherapy for patients with advanced solid tumors [4] - The ATR patent estate consists of four issued U.S. patents, one pending U.S. application, one international application, and 21 granted patents, including one issued in Japan in 2025, with existing patents expected to remain in force through 2035-2037 [4] Company Overview - Aprea is focused on developing innovative cancer therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, aiming to reduce toxicity associated with traditional treatments [6] - The company's lead programs, APR-1051 and ATRN-119, are small-molecule inhibitors targeting solid tumor indications [7]

Core Insights - Aprea Therapeutics has appointed Dr. Eugene Kennedy as Chief Medical Advisor, enhancing its clinical leadership during a pivotal phase of its WEE1 inhibitor APR-1051 development [1][2][3] Company Overview - Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies that target cancer-specific vulnerabilities while minimizing harm to healthy cells [6] - The company's lead programs include APR-1051, an oral small-molecule WEE1 kinase inhibitor, and ATRN-119, a small molecule ATR inhibitor, both aimed at treating solid tumors [7] Recent Developments - The appointment of Dr. Kennedy follows early clinical proof-of-concept results from a Phase 1 dose-escalation study of APR-1051 in patients with advanced solid tumors [2][3] - Dr. Kennedy brings over 20 years of experience in oncology clinical development and regulatory strategy, which is expected to strengthen Aprea's clinical efforts [2][4] Strategic Goals - The company aims to optimize dose and patient selection for its WEE1 program and advance its DNA damage response (DDR) pipeline towards key clinical and regulatory milestones [3][4] - Dr. Kennedy expressed alignment with Aprea's strategy to lead in DDR inhibition, emphasizing the potential to transform treatment approaches for difficult-to-treat cancers [3][5]

FDA Approvals & Rejections - Intellia Therapeutics has received FDA approval to resume its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) targeting hereditary transthyretin amyloidosis with polyneuropathy, increasing target enrollment from 50 to 60 patients [2][4] - Outset Medical's next-generation Tablo Hemodialysis System has been granted FDA 510(k) clearance, making it the first dialysis device to meet enhanced cybersecurity standards, with shipping expected to begin in Q2 2026 [6][7] - OKYO Pharma has received positive feedback from the FDA for its Phase 2b/3 trial design for Urcosimod, a candidate for neuropathic corneal pain, with plans to start the trial in the first half of 2026 [8][9] - REGENXBIO has faced clinical holds on its RGX-111 and RGX-121 gene therapy programs due to a case of CNS tumor in a child treated with RGX-111, although no similar findings were reported in other patients [10][11] - Almirall has received NMPA approval for Seysara in China for treating moderate-to-severe acne vulgaris, expanding its dermatology portfolio in the region [12][13] Clinical Trials - Breakthroughs - Aprea Therapeutics reported early clinical activity for APR-1051 in endometrial cancer, achieving a 50% reduction in target lesion size in a patient with PPP2R1A-mutated uterine serous carcinoma [19][21] - Fractyl Health's Revita demonstrated positive results in weight maintenance after GLP-1 drug discontinuation, showing a 4.5% weight regain compared to 7.5% in the sham group [22][24] - Ascletis Pharma announced positive Phase 3 results for Denifanstat in moderate-to-severe acne vulgaris, focusing on long-term safety in a trial with 240 patients [25][26] - GRI Bio reported new gene expression data from its Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis, showing significant improvements in lung injury and fibrosis progression [27][28] - Cardiff Oncology announced encouraging results from its Phase 2 trial of Onvansertib in RAS-mutated metastatic colorectal cancer, with a well-tolerated regimen and plans to advance to a registrational program [31][32] - Genentech's CT-388 Phase 2 trial for obesity showed a significant placebo-adjusted weight loss of 22.5% at 48 weeks, with a high percentage of participants achieving significant weight loss [34][36] - Sarepta Therapeutics reported positive three-year results from its EMBARK study for ELEVIDYS in Duchenne muscular dystrophy, showing significant slowing of disease progression in treated patients [38][41] Deals - YD Bio Limited has signed a letter of intent to acquire Safe Save Medical for approximately $26.87 million, aiming to enhance its capabilities in advanced cellular therapeutics [14][15][17]